AI Article Synopsis
- - Recent advancements in cancer treatment have led to a rise in the use of oral antineoplastic agents, with projections suggesting that 25% of these agents will be administered orally in the near future.
- - While oral medications offer advantages, they also present challenges such as low patient adherence and safety concerns, highlighting the need for better management of patients.
- - Effective patient education is crucial for improving adherence to these therapies, understanding treatment plans, and managing side effects, which can ultimately enhance treatment outcomes and quality of life.
Article Abstract
Recent progress in cancer treatment has increased the use of oral antineoplastic agents. It is now estimated that at least 25% of the existing antineoplastic agents are planned to be used as oral agents and this mode of administration is likely to increase in the coming years. The use of oral anti- neoplastic agents affects many aspects of cancer treatment, and despite advantages, it also poses challenges to health care professionals and patients, many of which refer to the adherence and safety. Low patient adherence demonstrates the need for better management and monitoring of patients on oral antineoplastic agents. Patient education is essential to maintain adherence to oral antineoplastic therapy, promoting a better understanding of the patient treatment regimen, treatment goals and potential side-effects, patient safety and implementation of self-care measurement. This article discusses the above-mentioned challenges, as well as the possibilities of patient and family education to improve adherence, outcomes of treatment and quality of life, and offers recommendations for practice and further research.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of pharmacist-managed oncology ambulatory care for patients with non-small cell lung cancer in Taiwan.
J Food Drug Anal
December 2024
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Non-small cell lung cancer (NSCLC) is commonly treated with tyrosine kinase inhibitors (TKIs). However, adverse events from such treatment can lead to treatment discontinuation and additional medical expenditures. Ambulatory care from oncology pharmacists in patient education and symptom management can benefit patients with NSCLC.
View Article and Find Full Text PDFCost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan.
J Food Drug Anal
December 2024
Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
This study was aimed to evaluate the cost-effectiveness of pembrolizumab with chemotherapy (pembrolizumab combination therapy) and compare it with standard-of-care platinum-based chemotherapy (chemotherapy alone) as a first-line treatment for metastatic nonsquamous NSCLC from the perspective of Taiwan's third-party-payer public health-care system. We used a partitioned survival model with an estimated time horizon of 10 years. The partitioned survival model uses Kaplan-Meier estimates of progression-free and overall survival from the KEYNOTE-189 clinical trial.
View Article and Find Full Text PDFAlanine supplementation enhancing cordycepin production in Cordyceps militaris via upregulation of Cns2 and Cns3 genes expression levels.
J Food Drug Anal
December 2024
Jiangxi Key Laboratory of Natural Microbial Medicine Research, College of Life Sciences, Jiangxi Science & Technology Normal University, Nanchang 330013, Jiangxi, China.
Cordycepin, a key bioactive compound produced by Cordyceps militaris, faces the challenge of low productivity for commercial use. In this study, alanine supplementation in Cordyceps militaris boosted cordycepin production, peaking at 3 mg/g with 12 g/L concentration. Transcriptome analysis revealed 1711 differentially expressed genes, Pathway analysis indicates that protein processing in the endoplasmic reticulum was the most affected pathway.
View Article and Find Full Text PDFExplainable Machine Learning to Predict Treatment Response in Advanced Non-Small Cell Lung Cancer.
JCO Clin Cancer Inform
January 2025
Emory University School of Medicine, Atlanta, GA.
Purpose: Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%. We sought to find out if a machine learning (ML) algorithm can perform better as a predictive biomarker than PD-L1 alone.
View Article and Find Full Text PDFVirtual screening and molecular dynamics simulations identify repurposed drugs as potent inhibitors of Histone deacetylase 1: Implication in cancer therapeutics.
PLoS One
January 2025
Center of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates.
Epigenetic processes are the critical events in carcinogenesis. Histone modification plays a crucial role in gene expression regulation, where histone deacetylases (HDACs) are key players in epigenetic processes. Inhibiting HDACs has shown promise in modern cancer therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!